<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>MR Mota | Tristan Snowsill</title>
    <link>/author/mr-mota/</link>
      <atom:link href="/author/mr-mota/index.xml" rel="self" type="application/rss+xml" />
    <description>MR Mota</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>Â© 2020 Tristan Snowsill</copyright><lastBuildDate>Tue, 01 Nov 2016 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_2.png</url>
      <title>MR Mota</title>
      <link>/author/mr-mota/</link>
    </image>
    
    <item>
      <title>AZACITIDINE FOR TREATING ACUTE MYELOID LEUKAEMIA: A NICE SINGLE TECHNOLOGY APPRAISAL</title>
      <link>/publication/tikhonova-2016-azacitidine-for-treating-acute-myeloid-leukaemia/</link>
      <pubDate>Tue, 01 Nov 2016 00:00:00 +0000</pubDate>
      <guid>/publication/tikhonova-2016-azacitidine-for-treating-acute-myeloid-leukaemia/</guid>
      <description></description>
    </item>
    
    <item>
      <title>MODEL-BASED COST-UTILITY ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR THE TREATMENT OF CANCER-TREATMENT INDUCED ANAEMIA IN THE UK NHS</title>
      <link>/publication/snowsill-2014-model-based-cost-utility-analysis-of-erythropoiesis-stimulating-agents/</link>
      <pubDate>Sat, 01 Nov 2014 00:00:00 +0000</pubDate>
      <guid>/publication/snowsill-2014-model-based-cost-utility-analysis-of-erythropoiesis-stimulating-agents/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
